Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.620
-0.090 (-1.91%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Employees
As of June 30, 2025, Neuphoria Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,956,181
Profits / Employee
-$46,204
Market Cap
10.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 8 | 0 | - |
| Jun 30, 2024 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NEUP News
- 1 day ago - Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process - GlobeNewsWire
- 8 days ago - PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 8 days ago - Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire
- 4 weeks ago - Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewsWire
- 2 months ago - Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - GlobeNewsWire
- 5 months ago - Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewsWire